Sutro Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. on November 21, 2023. The report discloses a significant executive leadership change and associated compensatory arrangements effective December 1, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive appointments and compensation.
Material Changes
The primary material change is the promotion of Jane Chung from Chief Commercial Officer to President and Chief Operating Officer. In connection with this promotion, her compensation package was modified as follows:
- Base Salary: Increased to $560,000 annually, effective December 1, 2023.
- Target Bonus: New target of up to 50% of base salary for fiscal year 2023.
- Stock Options: Grant of options to purchase 35,000 shares of common stock, vesting monthly over four years with a ten-year term.
- Restricted Stock Units (RSUs): Grant of 100,000 RSUs, vesting annually over four years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that Ms. Chung has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K and confirms no family relationships with other directors or officers.
Investor Verification Checklist
- Verify the exact closing price of Sutro Biopharma common stock on December 1, 2023, to determine the exercise price of the new stock options.
- Review the Company's 2018 Equity Incentive Plan to confirm the availability of shares for the new grants.
- Confirm the vesting schedules and performance conditions for the new bonus and equity awards.
- Check for any subsequent filings regarding the departure of the previous President or Chief Operating Officer.